摘要
肝癌TACE后肿瘤复发率较高,这可能与栓塞后肿瘤缺氧及残存肿瘤细胞缺氧应答有关。替拉扎明是一种靶向缺氧细胞毒性药物,可以增强肿瘤放疗和化疗效果。TACE联合替拉扎明治疗肝癌有望达到协同抗肿瘤作用。本文就TACE治疗肝癌的原理与不足、替拉扎明靶向缺氧细胞毒性治疗机制及现状、TACE联合替拉扎明治疗肝癌的可行性及研究进展进行综述。
The recurrence rate of hepatocellular carcinoma(HCC) after transcatheter chemoembolization(TACE) is high, which may be related to the embolization-induced tumor hypoxia and the hypoxia response of residual tumor cells. Tirapazamine is a toxic drug targeting hypoxic tumor cells, and it can enhance the efficacy of radiotherapy and chemotherapy. Combination use of TACE and tirapazamine is expected to achieve synergistic anti-tumor effect. This paper aims to make a comprehensive review about TACE treatment of HCC,focusing on its therapeutic principles and inadequacies, the mechanism and current status of tirapazamine targeted hypoxia cell therapy, the feasibility and research progress in TACE combined with tirapazamine in treating HCC.(J Intervent Radiol, 2021, 30: 846-850)
作者
李卿
梁斌
LI Qing;LIANG Bin(Department of Radiology,Affiliated Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei Province 430022,China)
出处
《介入放射学杂志》
CSCD
北大核心
2021年第8期846-850,共5页
Journal of Interventional Radiology
关键词
癌
肝细胞
化疗栓塞
治疗性
替拉扎明
缺氧
hepatocellularcarcinoma
chemoembolization
therapeutic
tirapazamine
hypoxia
